Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPK-88004 Dose-ranging Study in Men With BPH
NCT03297398Phase 2Terminated
- Sponsor
- OPKO Health
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LY2452473 in benign prostatic hyperplasia (BPH) (3 arms), sponsored by OPKO Health. Primary endpoint: Change From Baseline in PSA (%) at 16 weeks. Started Feb 2018; status: terminated.
02
Drugs
LY2452473
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT03297398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297398.